Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Analysts at Lifesci Capital

Lifesci Capital started coverage on shares of Palvella Therapeutics (NASDAQ:PVLA) in a report released on Monday morning,Benzinga reports. The brokerage issued an outperform rating and a $90.00 target price on the stock.

PVLA has been the topic of a number of other research reports. Truist Financial began coverage on Palvella Therapeutics in a report on Monday, July 21st. They issued a “buy” rating and a $56.00 target price on the stock. Canaccord Genuity Group lowered their price objective on shares of Palvella Therapeutics from $53.00 to $52.00 and set a “buy” rating on the stock in a research report on Friday, May 16th. HC Wainwright reiterated a “buy” rating and issued a $38.00 price objective on shares of Palvella Therapeutics in a research note on Wednesday, April 30th. Finally, Chardan Capital started coverage on shares of Palvella Therapeutics in a research report on Wednesday, April 9th. They issued a “buy” rating and a $50.00 target price for the company. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Palvella Therapeutics currently has an average rating of “Buy” and a consensus target price of $52.22.

Palvella Therapeutics Stock Up 1.8%

Shares of NASDAQ:PVLA opened at $37.20 on Monday. The company’s fifty day moving average is $27.28 and its two-hundred day moving average is $23.66. The company has a market cap of $411.43 million, a P/E ratio of -3.07 and a beta of -0.01. Palvella Therapeutics has a 12-month low of $11.17 and a 12-month high of $40.50.

Palvella Therapeutics (NASDAQ:PVLA) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.74) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.40) by $2.66. Equities research analysts anticipate that Palvella Therapeutics will post -3.69 earnings per share for the current year.

Hedge Funds Weigh In On Palvella Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PVLA. Clio Asset Management LLC bought a new stake in Palvella Therapeutics in the second quarter worth approximately $2,063,000. Goldman Sachs Group Inc. acquired a new stake in shares of Palvella Therapeutics in the 1st quarter valued at $533,000. Woodline Partners LP acquired a new stake in shares of Palvella Therapeutics in the 1st quarter valued at $5,435,000. Millennium Management LLC bought a new stake in Palvella Therapeutics in the first quarter worth $7,553,000. Finally, AWM Investment Company Inc. acquired a new position in Palvella Therapeutics during the first quarter worth $1,943,000. Institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.